Aromatase inhibitors (AIs) are a class of drugs that have become pivotal in the treatment of hormone receptor-positive breast cancer, particularly in postmenopausal women. They work by inhibiting the aromatase enzyme, which is responsible for converting androgens into estrogens, thereby lowering estrogen levels in the body. This reduction is essential for controlling the growth of certain types of breast cancer that rely on estrogen for proliferation.
https://www.green-support.nl/a-comprehensive-review-of-aromatase-inhibitors/
1. Types of Aromatase Inhibitors
There are three main types of aromatase inhibitors currently used in clinical practice:
- Non-steroidal aromatase inhibitors: These include anastrozole (Arimidex) and letrozole (Femara). They are typically used as the first-line treatment in hormone receptor-positive breast cancer.
- Steroidal aromatase inhibitors: The most well-known is exemestane (Aromasin). It not only inhibits aromatase but also has additional actions as a steroid.
- Combination therapies: Some treatment regimens combine AIs with other cancer therapies, such as tamoxifen or CDK4/6 inhibitors, to enhance efficacy.
2. Mechanism of Action
Aromatase inhibitors work by blocking the activity of the aromatase enzyme, resulting in significantly decreased levels of estrogen in the bloodstream. This is particularly effective in postmenopausal women, where most circulating estrogens are derived from the conversion of androgens. By lowering estrogen levels, AIs help to slow the growth and spread of estrogen-dependent tumors.
3. Indications for Use
Aromatase inhibitors are primarily indicated for:
- Postmenopausal women with hormone receptor-positive breast cancer.
- Adjuvant therapy following surgery.
- Advanced or metastatic breast cancer when surgery is not an option.
4. Side Effects
While generally well-tolerated, aromatase inhibitors can cause several side effects, including:
- Joint pain or stiffness.
- Hot flashes.
- Fatigue.
- Bone density loss, increasing the risk of osteoporosis and fractures.
5. Conclusion
Aromatase inhibitors represent a cornerstone in the management of hormone receptor-positive breast cancer in postmenopausal women. With various options available and ongoing research into their combinations and long-term effects, AIs continue to play a significant role in improving patient outcomes. As with any medication, the decision to use aromatase inhibitors must be tailored to the individual patient’s needs and circumstances, weighing the benefits against potential side effects.